1 / 28

Second-Generation Antidepressants for Treating Adult Depression—An Update

Second-Generation Antidepressants for Treating Adult Depression—An Update. Prepared for: Agency for Healthcare Research and Quality (AHRQ) www.ahrq.gov. Outline of Material. The comparative effectiveness review (CER) process Background

quon-mclaughlin
Télécharger la présentation

Second-Generation Antidepressants for Treating Adult Depression—An Update

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Second-Generation Antidepressants for Treating AdultDepression—An Update Prepared for: Agency for Healthcare Research and Quality (AHRQ) www.ahrq.gov

  2. Outline of Material • The comparative effectiveness review (CER) process • Background • Questions addressed in the CER on second-generation antidepressants for adults with major depressive disorder (MDD): • Overall comparative effectiveness of treatments for MDD • Treating patients with unresponsive or recurrent disease • Treating symptoms that accompany depression • Comparative adverse effects • Evidence available on effectiveness and adverse effects in different patient subpopulations • Conclusions

  3. Agency for Healthcare Research and Quality (AHRQ) Comparative Effectiveness Review (CER) Development • Topics are nominated through a public process, which includes submissions from health care professionals, professional organizations, the private sector, policymakers, the public, and others. • A systematic review of all relevant clinical studies is conducted by independent researchers, funded by AHRQ, to synthesize the evidence in a report summarizing what is known and not known about the select clinical issue. The research questions and the results of the report are subject to expert input, peer review, and public comment. • The results of these reviews are summarized into Clinician Research Summaries and Consumer Research Summaries for use in decisionmaking and in discussions with patients. The Research Summaries and the full report are available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm. Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  4. Rating the Strength of Evidence From the Comparative Effectiveness Review • The strength of evidence was classified into four broad categories: Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  5. Background: Prevalence of Depressive Disorders • Depressive disorders such as major depressive disorder (MDD), dysthymia, and subsyndromal depression may be serious, disabling illnesses. • MDD affects more than 16 percent of adults at some point during their lifetimes. • In 2000, the economic burden of depressive disorders in the United States was estimated to be $83.1 billion. Likely, this number has increased during the past 10 years. More than 30 percent of these costs are attributable to direct medical expenses. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Text rev. 2000. Birnbaum HG, Ben-Hamadi R, Greenberg PE, et al. Pharmacoeconomics 2009;27(6):507-17. PMID: 19640013. Greenberg PE, Kessler RC, Birnbaum HG, et al. J Clin Psychiatry 2003 Dec;64(12):1465-75. PMID: 14728109. Kessler RC, Berglund P, Demler O, et al. JAMA 2003;289(23):3095-105. PMID: 12813115.

  6. Background: Treatment for Depression • Pharmacotherapy dominates the medical management of depressive disorders, including first-generation and the more recently developed second-generation antidepressants. • First-generation antidepressants include: • Tricyclic antidepressants • Monoamine oxidase inhibitors • Second-generation antidepressants dominate the medical management of depressive disorders and include: • Selective serotonin reuptake inhibitors (SSRIs) • Serotonin and norepinephrine reuptake inhibitors (SNRIs) • Selective serotonin and norepinephrine reuptake inhibitors (SSNRIs) • Other drugs with related mechanisms of action that selectively target neurotransmitters • The mechanism of action of most of these agents is poorly understood, but they most likely work through their effects on neurotransmitters such as serotonin, norepinephrine, or dopamine in the central nervous system. Olfson M, Marcus SC.Arch Gen Psychiatry 2009 Aug;66(8):848-56. PMID: 19652124.

  7. Background: Antidepressant Medications • In general, the efficacies of first- and second-generation antidepressant medications are similar. • However, first-generation antidepressants often produce multiple side effects that many patients find intolerable, and the risk for harm when taken in overdose or in combination with certain medications is high. • Because of their relatively favorable side-effect profile, the second-generation antidepressants play a prominent role in managing patients with major depressive disorder and are the focus of this presentation. Geddes JR, Freemantle N, Mason J, et al. Cochrane Database Syst Rev 2007 Jul 18;(3):CD001851. PMID: 17636689. Williams JW, Mulrow CD, Chiquette E, et al. Ann Intern Med 2000 May 2;132(9):743-56. PMID: 10787370.

  8. Comparative Effectiveness Review on Second-Generation Antidepressants for Adults With Depression • A systematic review of 248 clinical studies published between January 1980 and January 2011 sought to determine the effectiveness, benefits, and adverse effects of second-generation antidepressants for adults with depression. • This presentation is provided to assist in decisionmaking and should not be construed to represent clinical recommendations or guidelines. The full report is available at www.effectivehealthcare. ahrq.gov/secondgenantidep.cfm. Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  9. Second-Generation Antidepressants Included in the 2011 Updated Review Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  10. Outcomes of Interest in Studies on Second-Generation Antidepressants for Depression Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  11. Overall Comparative Effectiveness of Second-Generation Antidepressants for Treating Major Depressive Disorder • Overall Comparative Effectiveness • Immediate-Release and Extended-Release Formulations • Treatment Adherence and Persistence Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  12. Overall Comparative Effectiveness of Second-Generation Antidepressants for Treating Adults With MDD • Overall, second-generation antidepressants have similar efficacy, effectiveness, and effects on quality of life (37% did not respond during 6 to 12 weeks of treatment; 53% did not achieve remission).Strength of Evidence: Moderate • Mirtazapine has a faster onset of action (1–2 weeks) than do citalopram, fluoxetine, paroxetine, and sertraline; however, response rates were similar after 4 weeks of treatment. Strength of Evidence: Moderate • Elderly patients (≥60 years) with major depressive disorder (MDD) had similar efficacy with second-generation antidepressants.Strength of Evidence: Moderate • Elderly patients (≥60 years) with MDD may experience some differences in adverse events from these drugs. Strength of Evidence: Low Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  13. Immediate-Release Versus Extended-Release Formulations of Second-Generation Antidepressants for Adults With MDD • Fluoxetine daily and fluoxetine weekly have similar response and remission rates.Strength of Evidence: Moderate • Paroxetine IR (immediate release) and paroxetine CR (controlled release) have similar response rates.Strength of Evidence: Moderate • One trial reported higher response rates for venlafaxine XR (extended release) than venlafaxine IR.Strength of Evidence: Low MDD = major depressive disorder Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  14. Adherence and Persistence in Second-Generation Antidepressants for Adults With MDD • Adherence rates were similar (strength of evidence: moderate) for the following comparisons: • Citalopram versus sertraline • Bupropion SR versus fluoxetine, paroxetine, or sertraline • Bupropion versus trazodone • Paroxetine IR versus paroxetine CR • Adherence rates in patients with major depressive disorder (MDD) were higher for fluoxetine weekly versus daily. • Strength of Evidence: Low • Adherence rates were similar in patients treated with paroxetine IR and those receiving paroxetine CR. • Strength of Evidence: Moderate • Patients with MDD refilled prescriptions for bupropion XL more frequently than for bupropion SR. • Strength of Evidence: Low Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  15. Comparative Effectiveness of Second-Generation Antidepressants in Continuation and Maintenance Phases • Preventing Relapse • Maintaining Remission • Treating Resistant or Refractory Depression Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  16. Comparative Effectiveness of Second-Generation Antidepressants in Continuation and Maintenance Phases • Maintaining Remission • Most second-generation antidepressants effectively maintain remission (prevent relapse and recurrence) with similar efficacy. Strength of Evidence: Moderate • Resistant or Refractory Depression • Venlafaxine may be modestly superior to other selective serotonin reuptake inhibitors; however, results on comparative effectiveness are mixed.Strength of Evidence: Low Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  17. Effectiveness of Second-Generation Antidepressants in Treating Symptoms That May Accompany Depression • Anxiety • Pain • Insomnia • Low Energy • Psychomotor Change • Melancholia • Somatization Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  18. Effectiveness in Treating Symptoms That May Accompany Depression • Second-generation antidepressants have similar efficacy for treating depression in patients who also have anxiety. Strength of Evidence: Moderate • Improvements in anxiety scores were similar among second-generation antidepressants for patients with depression.Strength of Evidence: Moderate • Paroxetine and duloxetine showed similar improvements in pain scores in patients with depression.Strength of Evidence: Moderate • Several second-generation antidepressants are equally effective in treating insomnia symptoms in patients with depression.Strength of Evidence: Low • There was insufficient evidence to determine the comparative efficacy of second-generation antidepressants in treating low energy, psychomotor changes, melancholia, or somatization. Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  19. Comparative Harms of Second-Generation Antidepressants • Overall Comparative Harms • Specific Adverse Events by Drug • Risk of Severe Adverse Events Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  20. Overall Comparative Harms of Second-Generation Antidepressants for Adults With Major Depressive Disorder • Overall rates of adverse events were similar among second-generation antidepressants, though incidence of specific adverse effectsdiffered across antidepressants. Strength of Evidence: High • Overall differences in formulations: • No differences in harms were found between fluoxetine daily and fluoxetine weekly or between venlafaxine IR and venlafaxine XR.Strength of Evidence: Moderate Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  21. Specific Comparative Harms of Second-Generation Antidepressants for Adults With MDD (1 of 3) Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  22. Specific Comparative Harms of Second-Generation Antidepressants for Adults With MDD (2 of 3) MDD = major depressive disorder Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  23. Specific Comparative Harms of Second-Generation Antidepressants for Adults With MDD (3 of 3) MDD = major depressive disorder; SSRI = selective serotonin reuptake inhibitor Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  24. Risks of Severe Adverse Events From Second-Generation Antidepressants for Adults With MDD MDD = major depressive disorder Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  25. Noncomparative Evidence on Adverse Effects: Diabetes, Fractures, and Bleeding • Unrated evidence on second-generation antidepressants shows: • An increased risk for diabetes in patients on recent long-term use (>24 months) of moderate to high doses of fluvoxamine, paroxetine, or venlafaxine. • An increased risk for fractures (hip and other fractures, except fractures of the forearms or spine) for patients on high-dose citalopram, fluoxetine, paroxetine, and sertraline. • An increased risk for upper gastrointestinal tract bleeding during treatment with selective serotonin reuptake inhibitors.

  26. Gaps in Knowledge (1 of 2) • The general efficacy of second-generation antidepressants for treating dysthymia and subsyndromal depression. • Differences in benefits and harms in subgroups such as the very elderly or patients with common comorbidities. • The most appropriate duration of antidepressant treatment for maintaining remission. • The effect of drug dosage on the risk of relapse or recurrence. Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  27. Gaps in Knowledge (2 of 2) • The most effective second-generation antidepressant in patients who either did not respond or could not tolerate a first-line treatment. • How combinations of antidepressants compare with monotherapy in treatment-resistant depression. • How outcomes of second-generation antidepressants differ in populations with accompanying symptoms such as anxiety, insomnia, pain, or fatigue. • The comparative risks of second-generation antidepressants with respect to rare but serious adverse effects such as suicidality, hyponatremia, hepatotoxicity, seizures, cardiovascular adverse events, and serotonin syndrome. Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Review No. 46. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.

  28. What To Discuss With Your Patients About Second-Generation Antidepressants • The benefits of the different second-generation antidepressants for treating their specific symptoms. • How they will know if their medication is working. • How to identify the potential adverse effects of the medications and how to handle them. • How long they may need to take their current antidepressant. • The importance of adhering to their treatment regimens and what to expect if they stop taking their medications such as withdrawal or discontinuation syndrome. • To always consult their health care provider before discontinuing any medication. • How their medications will affect the symptoms that may be accompanying their depression such as anxiety, insomnia, or chronic pain. • Their comorbidities and the medications they may be taking for them and how these may influence their depression-related outcomes.

More Related